来宝网Logo

热门词:生物显微镜 水质分析仪 微波消解 荧光定量PCR 电化学工作站 生物安全柜

现在位置首页>技术资料首页>行业动态>公司动态>Idaho Technology更名为BioFire Diagnostics

Idaho Technology更名为BioFire Diagnostics

互联网2012年9月1日 14:52 点击:2959

 美国Idaho Technology     美国Biofire Diagnostics    
 

爱达荷州科技有限公司( Idaho Technology)2012年8月28日宣布,它已经改变了公司的名字,为BioFire诊断,公司表示改名能更准确地反映其业务策略和强劲的势头。
 

Idaho Technology, Inc. Becomes BioFire Diagnostics, Inc.(TM)
Name Change Reflects Growing Breadth of Services in Molecular Diagnostics

SALT LAKE CITY, Aug. 28, 2012 (GLOBE NEWSWIRE) -- Idaho Technology, Inc., today announced it has changed the corporate name to BioFire Diagnostics, Inc. to more accurately reflect its business strategy and strong momentum in the marketplace. The Company has also re-launched its website (www.BioFireDx.com) to reveal its new branding.

"We are excited to announce our new name to our customers and industry members," said Kirk Ririe, Chief Executive Officer of BioFire Diagnostics. "The new name reflects the passion and energy of the Company and management team, and highlights our expanded presence in the clinical diagnostics market. We have established strong momentum in the diagnostics marketplace and the new branding under BioFire Diagnostics better reflects the markets we serve. We believe we are in an excellent position to continue building our business by driving growth of our broad molecular diagnostic product portfolio."

BioFire Diagnostics will continue to focus on leveraging its novel FilmArray® pathogen detection system to develop multiplex diagnostic tests for various clinical applications. The FilmArray Respiratory Panel (RP) is FDA-cleared for 20 viral and bacterial respiratory pathogens. BioFire now provides the only FDA cleared clinical diagnostic test for 8 of the 20 organisms in its panel. Besides the FilmArray RP, the Company is developing similar FilmArray panels for pathogen identification in blood culture, gastrointestinal infections, meningitis and much more.

In addition to its enthusiasm around the clinical diagnostics space, BioFire will continue to lead in the development of reliable and sensitive biosurveillance products such as its PCR-based biodetection system RAZOR® EX and the FilmArray BioSurveillance System.

About BioFire Diagnostics, Inc.

BioFire Diagnostics, Inc. is a privately held clinical diagnostics company based in Salt Lake City, Utah. The Company manufactures and distributes its proprietary diagnostic respiratory panel, FilmArray RP, which operates on its user-friendly FilmArray system, to hospital-based clinical laboratories in the U.S. and EU. BioFire is continuing to develop a broader test menu for its FilmArray system, including a blood culture ID panel, gastrointestinal panel, and a meningitis panel. The Company prides itself in a comprehensive understanding of what matters most to its customers, and continues to make great strides to ensure that its products remain reliable, user-friendly, and on the cutting edge of innovation.

The Company also currently holds over 70 patents related to polymerase chain reaction (PCR). The Company has used its extensive patent portfolio to successfully market nearly 200 products to the clinical, research and military markets. BioFire collaborates with various U.S. governmental agencies including the Department of Health and Human Services and the Department of Defense. Additionally, researchers, medical technicians, law enforcement officers, and soldiers in the field use company devices to detect or study disease-causing organisms.

For further information, please visit www.BioFireDx.com.

CONTACT: BioFire Diagnostics, Inc.
         Rachel Jones
         801-736-6354 x438
         Rachel@biofiredx.com
         
         The Ruth Group (on behalf of BioFire Diagnostics)
         Victoria Aguiar (media)
         646-536-7013
         Vaguiar@theruthgroup.com
(来源: 互联网 )


全年征稿 / 资讯合作

联系邮箱:kefu@labbase.net

版权与免责声明

  • 凡本网注明“来源:来宝网”的所有作品,版权均属于来宝网,转载请必须注明来宝网, //www.next-search.com,违反者本网将追究相关法律责任。
  • 本网转载并注明自其它来源的作品,目的在于传递更多信息,并不代表本网赞同其观点或证实其内容的真实性,不承担此类作品侵权行为的直接责任及连带责任。其他媒体、网站或个人从本网转载时,必须保留本网注明的作品来源,并自负版权等法律责任。
  • 如涉及作品内容、版权等问题,请在作品发表之日起一周内与本网联系,否则视为放弃相关权利。